

CV Prof. Dr. rer. nat. Holger Grüll

Name Grüll, Holger, Univ.-Prof. Dr. rer. nat.

Institute: Department of Diagnostic and Interventional Radiology,
chair *Experimental Imaging and Image-guided Therapy*
University Hospital Cologne, Germany
Kerpener Str 62
50937 Cologne



Dept. of Chemistry
University of Cologne, Germany
Greinstraße 4
50939 Cologne

Email: holger.gruell@uni-koeln.de; holger.gruell@uk-koeln.de

Scientific career

Since 2016 Full Professor, Department of Radiology, University Hospital Cologne, chair experimental imaging and image guided therapy.

Since 2021 Professor, Department of Chemistry, cooptation.

2007 - 2020 Full professor, Faculty of Biomedical Technology, Eindhoven University of Technology, The Netherlands. Chair: molecular imaging and image guided interventions (part-time).

2000 – 2016 Principal Scientist Philips Research, Eindhoven, The Netherlands. Head of laboratory for translational research, preclinical imaging and image-guided interventions.

1999 – 2000 Postdoctoral fellow, Ben Gurion University of the Negev and Weizmann Institute of Science, Israel (Prof. Dr. Rachel Yerushalmi-Rozen)

1997 – 1999 Postdoctoral fellow, National Institute of Standards and Technology, Gaithersburg, MD, USA (Charles Han, PhD.)

1997 Guest scientist, Ben Guiron University of the Negev, Israel (Prof. Dr. Rachel Yerushalmi-Rozen)

Academic education

1993-1996 PhD in Physical Chemistry, University of Cologne (Prof. Dr. Woermann)
1988-1993 Chemistry, University of Cologne

Scientific degrees

02/2020 Prüfarzt (certificate to act as PI for BfArM/MPG clinical trials)

12/1996 PhD., Department of Physical Chemistry, University of Cologne, “Interfacial Phenomena at the liquid/solid interface during phase separation” (Supervisor: Prof. Dietrich Woermann, PhD.)

06/1993 Diplom (Masters) in Chemistry , University of Cologne

CV Prof. Dr. rer. nat. Holger Gröll

Honors/ Awards/ Memberships

2014 - 2018	Coordinator of the large-scale EU FP7 project IPACT (Image guided Pancreatic Cancer Therapy)
2011	Award for the Most Innovative Research Proposal Area Health, Eindhoven University 2011
2011	Teaching Award as best Masters lecturer of the University Eindhoven
2002	Coordinator of the Dutch STW project "Prospects" (Protein sensing array diagnostics on a chip)
1997	Fellowship of the Alexander von Humboldt Foundation
Memberships	ISTU, ESHO, ESMI, EUFUS

Profile

Holger Gröll studied chemistry in Cologne, Germany, and received 1996 his PhD in Physical Chemistry. After his PhD, he was working several years as postdoc and guest researcher at the Ben-Gurion University of the Negev, Beer Sheva (Israel), the National Institute of Standards and Technology (NIST) in Gaithersburg (USA), and again the Ben-Gurion University of the Negev working on polymers, nanoparticles, polymeric membranes and drug delivery systems. In 2000, he started his career at the Philips Research Laboratory in Eindhoven, The Netherlands, and became later responsible for the in vivo research on molecular imaging and therapeutic applications. Since 2007, Dr. Gröll and his team investigated new applications of MR-HIFU such as treatment of bone metastasis, ablation of sarcomas and pancreatic cancer, as well as hyperthermia for drug delivery using temperature sensitive liposomes. In 2007, Dr. Gröll was appointed professor at the Eindhoven University of Technology holding a chair for Molecular Imaging and Image-guided Interventions. In 2016, Dr. Gröll received an appointment as full professor at the department of radiology, University Hospital Cologne, where he is now responsible for the translational research and application of MR-HIFU including clinical trials. Main HIFU research areas are ultrasound-induced drug delivery with stimuli responsive nanoparticles and bioeffects of ultrasound for application in pancreatic cancer and bone disease. Another research area is the multimodal imaging of tumors, tumor microenvironment and immune response using new radioactive tracers and contrast agents. Dr. Gröll also obtained his qualification and permit to act as a PI for clinical trials in spring 2020. He recently obtained funding to run two first-in-man clinical trials for MR-HIFU treatment of facet joint syndrome and pancreatic cancer scheduled to start in 2021.